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BACKGROUND and PURPOSE:  Bisphosphonates are a class of pharmaceuticals used to treat 
diverse bone disorders such as osteoporosis, Paget’s disease, and multiple myeloma.  They 
constitute a class of drugs which adhere to bony surfaces and interfere with the resorptive activity 
of osteoclasts.  They also represent a potential countermeasure towards the loss of bone mass 
experienced by astronauts during spaceflight.  Recently, the medical literature has revealed cases 
of osteonecrosis of the jaw in individuals receiving intravenous bisphosphonate therapy with a 
smaller number of cases occurring in individuals receiving the oral form of the medication.  Risk 
management for long duration missions requires consideration of mission success and lifetime 
health care of astronauts. 
 
METHODS:  We performed MEDLINE and PubMed searches (1966 – December 2006) 
using the following keywords:  osteonecrosis, jaw, bisphosphonates.  Additional 
references were obtained from the citations of the retrieved articles. 
 
RESULTS:  Injectable bisphosphonates such as pamidronate and zoledronic acid have been 
highlighted recently in the literature due to a possible link with osteonecrosis of the jaw.  The 
mechanism of action remains unclear but may be linked to physiologic microdamage in the 
jawbones resulting from suppression of bone metabolism.  The most predisposing factors appear 
to be the type and dose of bisphosphonate used, a history of dental surgery, trauma, and/or dental 
infection.  In addition, patients diagnosed with a malignancy such as breast cancer or multiple 
myeloma, who have been on intravenous bisphosphonate therapy for several months seem to be 
at increased risk. 
The use of oral bisphosphonates appears to place patients more at risk from acute events 
such as gastrointestinal tract injury or perforation.  Although some studies report little to no 
increase in GI events compared to placebo, we must remember that in microgravity, astronauts 
may be unable to comply with medication instructions.  They may have difficulty remaining 
upright for the required 30-45 minutes post-ingestion.  We are currently unaware if this inability 
to comply with instructions on the package insert may lead to an increased risk for GI events. 
There is a potential long-term complication that resides with both forms of 
bisphosphonate therapy.  In order to repair normally occurring physiologic microdamage to bone, 
both osteoclastic resorption and osteoblastic bone deposition must be functional.  Controversy 
exists in the literature regarding whether prolonged use of bisphosphonates may lead to the 
suppression of bone turnover and accumulation of microdamage. 
   
CONCLUSIONS:  Bisphosphonates are a powerful class of drugs that suppress bone turnover, 
but may cause serious adverse clinical events such as gastrointestinal tract injury or osteonecrosis 
of the jaw.  Unfortunately, little to no data exists currently which may help us provide answers 
regarding the risks of their use in a healthy astronaut cohort.  While controversy exists in the 
literature regarding their mechanism and long-term consequences, the potential mission impact or 
lifetime health care impact of an adverse clinical event resulting from bisphosphonate therapy 
must be considered. 
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